Alcobra Ltd. to Present at Upcoming Investment Conferences Company Will Host Corporate Update Conference Call & Webcast on November 17

TEL AVIV, Israel, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced upcoming corporate presentations at the Stifel 2015 Healthcare Conference and the Jefferies Autumn 2015 Global Healthcare Conference. The company will host a conference call and webcast on November 17 to provide a corporate update and discuss third quarter 2015 financial results.

Conference Call & Webcast
Tuesday, November 17 @ 8:30am Eastern
Domestic: 855-469-0611
International: 484-756-4341
Passcode: 56489875
Replays available through December 1, 2015
Domestic: 855-859-2056
International: 404-537-3406
Passcode: 56489875
Stifel 2015 Healthcare Conference
Date: Tuesday, November 17
Time: 11:00am ET
Location: Lotte New York Palace, New York, NY
Presenter: Dr. Yaron Daniely, CEO
Jefferies Autumn 2015 Global Healthcare Conference
Date: Thursday, November 19
Time: 12:40pm GMT (7:40 am ET)
Location: The Mayfair Hotel, London, UK
Presenter: Dr. Yaron Daniely, CEO

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website,, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Inquiries Sam Brown, Inc. Mike Beyer 312-961-2502 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661

Source:Alcobra Ltd.